In fact, the regulation by PKCδ of its downstream signaling proteins JNK/ERK and the inhibition of RANTES/CCL5-induced MMP-1 and MMP-13 expression by Rottlerin suggest that PKCδ might be a relevant therapeutic target in RA. The gene discussed is PRKCD; the disease is rheumatoid arthritis.